Beyond Rebates: PhRMA Wants HHS To ‘De-Link’ Supply Chain Compensation From List Price
Executive Summary
Focus should not be limited to rebates in Medicare Part D, manufacturers advise in comments on HHS drug pricing blueprint. Pharmacy benefit managers raise anti-trust issues with shift to upfront discounts.
You may also be interested in...
Express Scripts Pushing Manufacturers To Lower List Prices By Offering Cheaper Brand Alternatives
Companies should introduce same drug under new NDC at lower list price to overcome difficulties of reducing list prices on existing brands, PBM says.
Part D Point-Of-Sale Rebates Losing Appeal? CBO Confirms Big Cost To Medicare
Congressional Budget Office agrees with the Office of Management and Budget that passing through negotiated rebates to Medicare Part D beneficiaries at the point-of-sale would significantly increase Medicare spending.
Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
The reform 'blueprint' might actually live up to its hype.